ESTRO 2024 - Abstract Book

S728

Clinical - Breast

ESTRO 2024

Conclusion:

As the landscape of oncological practices rapidly evolves, clinical trials must adapt to these changes while upholding scientific rigor. This study demonstrated that swift adjustments to trial designs using validated tools enabled the achievement of primary endpoints in a phase three randomized controlled trial in breast cancer. Going forward, the findings from this study can advocate for the incorporation of new tools, such as PRO-CTCAE, to obtain cost effective healthcare system data and reduce out-of-pocket expenses for patients, thereby minimizing unnecessary hospital visits.

Keywords: Breast, clinical trials, Pragmatic

References:

Cole KM, Clemons M, Alzahrani M, Liu M, Larocque G, MacDonald F, et al. Vasomotor symptoms in early breast cancer —a “real world” exploration of the patient experience. Support Care Cancer. 2022 May;30(5):4437– 46.

Basulaiman B, Awan AA, Fergusson D, Vandermeer L, Arnaout A, Hilton J, et al. Creating a pragmatic trials program for breast cancer patients: Rethinking Clinical Trials (REaCT). Breast Cancer Res Treat. 2019 Aug;177(1):93 – 101.

Fallowfield LJ, Leaity SK, Howell A, Benson S, Cella D. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT ‐ B. Breast Cancer Res Treat. 1999 May;55(2):187 – 97.

Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993 Mar;11(3):570 – 9.

Herdman M, Gudex C, Lloyd A, Janssen Mf, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011 Dec;20(10):1727 – 36.

3399

Proffered Paper

DBCG IMN2: Internal mammary node irradiation in 4541 high-risk breast cancer patients treated 2007-2014

Anders W. Mølby Nielsen 1 , Lise B. J. Thorsen 1,2 , Jens Overgaard 1 , Demet Özcan 1,3 , Louise W. Matthiessen 4 , Else Maae 5 , Marie L.H. Milo 6 , Mette H. Nielsen 7 , Trine Tramm 1,3 , Birgitte V. Offersen 1,2,8 1 Aarhus University Hospital, Department of Experimental Clinical Oncology, Aarhus, Denmark. 2 Aarhus University Hospital, Department of Oncology, Aarhus, Denmark. 3 Aarhus University Hospital, Department of Pathology, Aarhus, Denmark. 4 Copenhagen University Hospital - Herlev and Gentofte, Department of Oncology, Copenhagen, Denmark. 5 Vejle Hospital, University Hospital of Southern Denmark, Department of Oncology, Vejle, Denmark. 6 Aalborg